2024年11月14日,国家医保局在苏州发布2026年商业健康保险创新药品目录调整结果,宣布该目录新增12种重大创新药品 12。调整后,2026年商业健康保险创新药品目录共包含28种药品 12。此次新纳入的药品包括全球首个实体瘤CAR-T疗法以及中国首个血友病基因治疗药物 12。
新版目录建立了商保创新药目录与基本医保目录的衔接机制,其中2个2025年的品种被纳入医保目录 1。同日发布的2026年国家医保药品目录也进行了大幅调整,新增107种药品,其中包含51个一类新药,创历史新高;调整后医保目录药品总数达到3331个(西药1935个、中成药1396个) 2。上述新版医保及商保创新药目录均将于2027年1月1日正式执行 2。
China's National Healthcare Security Administration (NHSA) announced on November 14, 2024, the release of the adjusted 2026 Commercial Health Insurance Innovative Drug Catalog 12. The updated list features 12 newly added medications, bringing the total number of drugs in this specific commercial insurance catalog to 28 12. This announcement was made alongside the release of the broader national medical insurance drug list during an event held in Suzhou 2.
The newly included commercial health insurance drugs encompass significant therapeutic innovations, including the world’s first CAR-T therapy for solid tumors and China’s first gene therapy for hemophilia 12. To enhance coordination between different coverage systems, a mechanism has been established to link the commercial insurance innovative drug list with the basic medical insurance list 1. As part of this integration, two products from the 2025 commercial list have been incorporated into the basic medical insurance catalog 1.
In parallel, the 2026 National Basic Medical Insurance Drug List saw the addition of 107 new drugs, among which are 51 Class I innovative medicines, marking a historic high for such entries 2. Following these adjustments, the total number of drugs in the basic medical insurance catalog reached 3,331, comprising 1,935 Western medicines and 1,396 Chinese patent medicines 2. Both the revised national medical insurance list and the commercial health insurance innovative drug catalog are scheduled to officially take effect on January 1, 2027 2.
评论
还没有评论,欢迎留下第一条。